|
PL4023249T3
(pl)
|
2014-04-23 |
2025-03-10 |
Modernatx, Inc. |
Szczepionki z kwasem nukleinowym
|
|
CN120842296A
(zh)
|
2015-09-21 |
2025-10-28 |
垂林克生物技术有限公司 |
用于合成5’-加帽rna的组合物和方法
|
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
|
CA3005968A1
(en)
|
2015-11-23 |
2017-06-01 |
The Regents Of The University Of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
EP3585895A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing
|
|
SG11201906297QA
(en)
|
2017-03-24 |
2019-10-30 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
EP3634449A4
(en)
|
2017-05-08 |
2021-03-17 |
Gritstone Oncology, Inc. |
ALPHAVIRUS NEOANTIGEN VECTORS
|
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
KR20250028535A
(ko)
*
|
2017-06-30 |
2025-02-28 |
코덱시스, 인코포레이티드 |
T7 rna 폴리머라제 변이체
|
|
EP3645712A4
(en)
|
2017-06-30 |
2021-07-07 |
Codexis, Inc. |
T7 RNA POLYMERASE VARIANTS
|
|
SG11201911430PA
(en)
|
2017-07-04 |
2020-01-30 |
Curevac Ag |
Novel nucleic acid molecules
|
|
WO2019036682A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
RNA VARIANTS POLYMERASE
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
EP3688161A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
|
WO2019067910A1
(en)
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
|
|
KR20200143391A
(ko)
*
|
2018-03-15 |
2020-12-23 |
비온테크 알엔에이 파마슈티컬스 게엠베하 |
5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
AU2019254591B2
(en)
|
2018-04-17 |
2025-12-11 |
CureVac SE |
Novel RSV RNA molecules and compositions for vaccination
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
WO2020002598A1
(en)
|
2018-06-28 |
2020-01-02 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
AU2019394996B2
(en)
|
2018-12-06 |
2025-11-06 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
AU2020220357B2
(en)
|
2019-02-11 |
2025-06-26 |
Ethris Gmbh |
mRNA purification by tangential flow filtration
|
|
AU2020224103A1
(en)
|
2019-02-20 |
2021-09-16 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
|
CN113874502A
(zh)
|
2019-03-11 |
2021-12-31 |
摩登纳特斯有限公司 |
补料分批体外转录方法
|
|
AU2020248337A1
(en)
|
2019-03-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
|
|
JP7631215B2
(ja)
|
2019-03-28 |
2025-02-18 |
インテリア セラピューティクス，インコーポレイテッド |
Ｔｔｒガイドｒｎａと、ｒｎａガイドｄｎａ結合剤をコードするポリヌクレオチドとを含む組成物および方法
|
|
MX2021011757A
(es)
|
2019-03-28 |
2021-12-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la expresión de polipéptidos.
|
|
US20220204978A1
(en)
*
|
2019-04-16 |
2022-06-30 |
The Regents Of The University Of California |
Protein translational control
|
|
KR20220023340A
(ko)
*
|
2019-04-26 |
2022-03-02 |
이더알엔에이 이뮤노테라피스 엔브이 |
mRNA 제형
|
|
BR112021023656A2
(pt)
*
|
2019-05-24 |
2022-02-01 |
Ultragenyx Pharmaceutical Inc |
Composições e métodos para tratamento de hemocromatose
|
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
EP4003508A1
(en)
|
2019-07-31 |
2022-06-01 |
Memorial Sloan Kettering Cancer Center |
Perfusion modulated tumor dose sculpting with single dose radiotherapy
|
|
CN114502204A
(zh)
|
2019-08-14 |
2022-05-13 |
库尔维科公司 |
具有降低的免疫刺激性质的rna组合和组合物
|
|
US20220307017A1
(en)
*
|
2019-08-29 |
2022-09-29 |
Universität Zürich |
Minimal Messenger RNAs and uses thereof
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
KR20220144416A
(ko)
|
2020-02-04 |
2022-10-26 |
큐어백 아게 |
코로나바이러스 백신
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
PL432884A1
(pl)
|
2020-02-12 |
2021-08-16 |
Uniwersytet Warszawski |
Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
|
|
PL248416B1
(pl)
*
|
2020-02-12 |
2025-12-08 |
Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia |
Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
|
|
CN115175916B
(zh)
*
|
2020-02-28 |
2025-02-14 |
国立研究开发法人科学技术振兴机构 |
加帽rna的制造方法
|
|
CN113151312B
(zh)
*
|
2020-03-02 |
2022-12-09 |
中国科学院微生物研究所 |
新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用
|
|
US12351834B2
(en)
|
2020-03-03 |
2025-07-08 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
|
AU2021236068A1
(en)
|
2020-03-09 |
2022-10-06 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
CA3173803A1
(en)
*
|
2020-04-21 |
2021-10-28 |
Karin Jooss |
Capping compounds, compositions and methods of use thereof
|
|
IL297419B2
(en)
|
2020-04-22 |
2025-02-01 |
BioNTech SE |
Coronavirus vaccine
|
|
CA3176844A1
(en)
|
2020-05-01 |
2021-11-04 |
Carlos G. PEREZ-GARCIA |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
KR20230013266A
(ko)
|
2020-05-19 |
2023-01-26 |
허드슨 인스티튜트 오브 메디컬 리서치 |
올리고뉴클레오티드
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
KR20230034333A
(ko)
*
|
2020-07-02 |
2023-03-09 |
라이프 테크놀로지스 코포레이션 |
트리뉴클레오티드 캡 유사체, 제조 및 이의 용도
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
CN116438308A
(zh)
|
2020-08-06 |
2023-07-14 |
磨石生物公司 |
多表位疫苗盒
|
|
EP4196128A4
(en)
|
2020-08-14 |
2024-06-12 |
Arcturus Therapeutics, Inc. |
METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
|
|
CN113122596B
(zh)
*
|
2020-08-20 |
2023-01-24 |
深圳市瑞吉生物科技有限公司 |
一种Cap2结构5′帽子类似物及其制备方法和应用
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
US20240246056A1
(en)
|
2020-09-01 |
2024-07-25 |
CureVac RNA Printer GmbH |
Manufacturing device for a pharmaceutical product
|
|
EP4208549A4
(en)
*
|
2020-09-04 |
2025-04-16 |
Verve Therapeutics, Inc. |
Compositions and methods for capping RNAs
|
|
CA3198727A1
(en)
|
2020-10-20 |
2022-04-28 |
St Pharm Co., Ltd. |
Oligonucleotide for 5'-capped rna synthesis
|
|
EP4251323B1
(en)
|
2020-11-27 |
2026-01-07 |
CureVac Manufacturing GmbH |
A device for preparing a dna product by means of capillary polymerase chain reaction
|
|
AU2021395736A1
(en)
|
2020-12-09 |
2023-07-27 |
BioNTech SE |
Rna manufacturing
|
|
IL303506A
(en)
|
2020-12-11 |
2023-08-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
US20240122865A1
(en)
|
2021-02-19 |
2024-04-18 |
Pfizer Inc. |
Methods of Protecting RNA
|
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
|
KR20220140140A
(ko)
|
2021-04-09 |
2022-10-18 |
한미정밀화학주식회사 |
캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
AU2022271249A1
(en)
|
2021-05-04 |
2023-11-16 |
BioNTech SE |
Immunogen selection
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
KR20240038705A
(ko)
|
2021-06-22 |
2024-03-25 |
인텔리아 테라퓨틱스, 인크. |
간 유전자의 생체 내 편집 방법
|
|
EP4368628A4
(en)
|
2021-07-05 |
2025-11-26 |
Japan Science & Tech Agency |
NUCLEOTIDE PURIFICATION PROCESS, NUCLEOTIDE PURIFICATION DEVICE, HYDROPHOBIC REAGENT AND HYDROPHOBIC SUBSTRATE
|
|
EP4116313A1
(en)
|
2021-07-07 |
2023-01-11 |
Westfälische Wilhelms-Universität Münster |
Cap analog for the 5'-end of eukaryotic messenger rnas
|
|
TW202320842A
(zh)
|
2021-07-29 |
2023-06-01 |
德商拜恩技術股份公司 |
用於治療黑色素瘤之組合物及方法
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
US20250002524A1
(en)
|
2021-07-30 |
2025-01-02 |
CureVac SE |
Cap analogs having an acyclic linker to the guanine derivative nucleobase
|
|
WO2023025404A1
(en)
|
2021-08-24 |
2023-03-02 |
BioNTech SE |
In vitro transcription technologies
|
|
CN113603739B
(zh)
|
2021-08-27 |
2024-08-23 |
上海兆维科技发展有限公司 |
一种加帽类似物及其应用
|
|
JP2024534871A
(ja)
*
|
2021-08-31 |
2024-09-26 |
ハンミ・ファイン・ケミカル・カンパニー・リミテッド |
ｍＲＮＡキャップ類似体及びその用途
|
|
US20240398940A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
CN113957108B
(zh)
*
|
2021-09-09 |
2025-01-10 |
上海兆维科技发展有限公司 |
一种加帽rna的合成方法以及加帽rna转录反应液
|
|
JP2024543721A
(ja)
|
2021-10-22 |
2024-11-22 |
ビオンテック・ソシエタス・エウロパエア |
オリゴ糖複合体及び用途
|
|
EP4169579A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
|
EP4286004A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
|
EP4186528A1
(en)
|
2021-11-30 |
2023-05-31 |
BioNTech SE |
Oligosaccharide complexes and uses
|
|
EP4169580A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
|
US20240417418A1
(en)
|
2021-10-22 |
2024-12-19 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
|
EP4285933A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
|
EP4402150A1
(en)
|
2021-10-22 |
2024-07-24 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
|
EP4169578A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
|
AU2022369405A1
(en)
|
2021-10-22 |
2024-05-09 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
|
EP4286003A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
|
EP4286394A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
|
EP4285932A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
|
EP4169534A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide complexes and uses
|
|
WO2023067123A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CA3237303A1
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
KR20230083197A
(ko)
|
2021-12-01 |
2023-06-09 |
에스티팜 주식회사 |
5'-캡핑된 rna 합성용 올리고뉴클레오티드
|
|
WO2023115495A1
(zh)
*
|
2021-12-23 |
2023-06-29 |
北京毅新博创生物科技有限公司 |
质谱法检测mRNA加帽效率的方法
|
|
EP4469065A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
KR20230123318A
(ko)
|
2022-02-16 |
2023-08-23 |
에스티팜 주식회사 |
5'-캡핑된 rna 합성용 올리고뉴클레오티드
|
|
GB2615784A
(en)
|
2022-02-18 |
2023-08-23 |
Phion Therapeutics Ltd |
mRNA vaccine
|
|
EP4261217A4
(en)
|
2022-02-28 |
2024-09-11 |
Guangzhou Henovcom Bioscience Co., Ltd. |
Compound for rna capping and application of compound
|
|
CN115260264B
(zh)
*
|
2022-02-28 |
2023-06-09 |
广州市恒诺康医药科技有限公司 |
用于rna加帽的化合物及其应用
|
|
JP2025507894A
(ja)
*
|
2022-03-01 |
2025-03-21 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
Ｒｎａをキャッピングするための組成物及び方法
|
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
US20230293646A1
(en)
|
2022-03-21 |
2023-09-21 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
|
US12522630B2
(en)
|
2022-03-31 |
2026-01-13 |
Hanmi Fine Chemical Co., Ltd. |
MRNA cap analog and uses thereof
|
|
CN114685588B
(zh)
*
|
2022-05-05 |
2024-03-29 |
江苏申基生物科技有限公司 |
一种含开环核苷结构的起始加帽寡核苷酸引物
|
|
GB2618818A
(en)
|
2022-05-18 |
2023-11-22 |
Phion Therapeutics Ltd |
Vaccine
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023235422A2
(en)
*
|
2022-05-31 |
2023-12-07 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
US20250215043A1
(en)
*
|
2022-05-31 |
2025-07-03 |
Nutcracker Therapeutics, Inc. |
Rna cap analogs and methods of use
|
|
CN119384498A
(zh)
|
2022-06-16 |
2025-01-28 |
因特利亚治疗公司 |
用于对细胞进行遗传修饰的方法和组合物
|
|
CN114853836B
(zh)
*
|
2022-06-24 |
2024-05-14 |
江苏申基生物科技有限公司 |
一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用
|
|
CN115057903B
(zh)
*
|
2022-06-22 |
2024-03-29 |
江苏申基生物科技有限公司 |
一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用
|
|
CN115109110B
(zh)
*
|
2022-06-22 |
2024-07-12 |
江苏申基生物科技有限公司 |
一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用
|
|
WO2023246860A1
(zh)
*
|
2022-06-22 |
2023-12-28 |
江苏申基生物科技有限公司 |
一种起始加帽寡核苷酸引物及其制备方法和应用
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
CN114941018B
(zh)
*
|
2022-06-28 |
2023-09-22 |
翌圣生物科技(上海)股份有限公司 |
cap1帽类似物的合成方法
|
|
KR20240010238A
(ko)
|
2022-07-15 |
2024-01-23 |
한미정밀화학주식회사 |
캡 유사체 및 이의 용도
|
|
CN117430652A
(zh)
*
|
2022-07-22 |
2024-01-23 |
广州市恒诺康医药科技有限公司 |
用于rna加帽的环状取代化合物及其应用
|
|
US11898186B1
(en)
|
2022-08-10 |
2024-02-13 |
Genscript Usa Inc. |
Compositions and methods for preparing capped mRNA
|
|
CN115925773A
(zh)
*
|
2022-08-23 |
2023-04-07 |
合肥华纳生物医药科技有限公司 |
一种新型信使核糖核酸帽类似物
|
|
CN120129688A
(zh)
*
|
2022-08-26 |
2025-06-10 |
垂林克生物技术有限公司 |
用于制备高度纯化的5′-加帽寡核苷酸的高效方法
|
|
WO2024051696A1
(zh)
*
|
2022-09-05 |
2024-03-14 |
广州市恒诺康医药科技有限公司 |
用于rna加帽的化合物及其应用
|
|
EP4583889A1
(en)
|
2022-09-09 |
2025-07-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
EP4583890A1
(en)
|
2022-09-09 |
2025-07-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024068674A1
(en)
|
2022-09-26 |
2024-04-04 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
|
WO2024075022A2
(en)
|
2022-10-04 |
2024-04-11 |
BioNTech SE |
Rna constructs and uses thereof
|
|
WO2024074634A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024084462A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
CN116143855B
(zh)
*
|
2022-11-08 |
2023-11-28 |
江苏申基生物科技有限公司 |
一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用
|
|
CN120418427A
(zh)
|
2022-12-23 |
2025-08-01 |
因特利亚治疗公司 |
用于基因组编辑的系统和方法
|
|
EP4397669A1
(en)
|
2023-01-06 |
2024-07-10 |
Westfälische Wilhelms-Universität Münster |
Photocaged cap analogs for the 5'-end of rnas
|
|
EP4652284A1
(en)
|
2023-01-20 |
2025-11-26 |
Astrazeneca AB |
Vaccine
|
|
CR20250341A
(es)
|
2023-01-20 |
2025-09-10 |
Astrazeneca Ab |
Moléculas de ácido nucleico
|
|
WO2024160895A1
(en)
|
2023-01-31 |
2024-08-08 |
CureVac SE |
Cap analogs with 5'-terminal acyclic guanosine derivative
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024185734A1
(ja)
|
2023-03-03 |
2024-09-12 |
株式会社ナティアス |
ポリリン酸化ヌクレオシド、ポリリン酸化ヌクレオシドの合成に用いられるリン酸部活性化ヌクレオチド及びその合成方法、ならびにリン酸部活性化ヌクレオチドを用いたポリリン酸化ヌクレオシドの合成方法
|
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN116356002A
(zh)
*
|
2023-03-28 |
2023-06-30 |
四川康德赛医疗科技有限公司 |
一种rna加帽效率的定量方法、试剂盒及其应用
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|
|
PE20252746A1
(es)
|
2023-03-29 |
2025-12-05 |
Scribe Therapeutics Inc |
Composiciones y metodos para el direccionamiento a pcsk9
|
|
CN118726510A
(zh)
*
|
2023-03-31 |
2024-10-01 |
苏州近岸蛋白质科技股份有限公司 |
一管法酶促合成加帽mRNA的方法
|
|
CN118772219B
(zh)
*
|
2023-04-04 |
2025-12-02 |
深圳瑞吉生物科技有限公司 |
一种用于核酸的5’端加帽的含卤化合物及其应用
|
|
AU2024260120A1
(en)
|
2023-04-27 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
EP4713483A1
(en)
|
2023-05-16 |
2026-03-25 |
CureVac RNA Printer GmbH |
Improved rna in vitro transcription using dna beads
|
|
CN121568708A
(zh)
|
2023-05-26 |
2026-02-24 |
库瑞瓦格欧洲股份公司 |
癌症抗原
|
|
WO2024260570A1
(en)
|
2023-06-23 |
2024-12-26 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
US20250026779A1
(en)
|
2023-06-29 |
2025-01-23 |
Nutcracker Therapeutics, Inc. |
Ethyl modified rna caps and methods of use
|
|
AU2024301706A1
(en)
|
2023-07-21 |
2026-02-05 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
WO2025027060A1
(en)
|
2023-07-31 |
2025-02-06 |
CureVac SE |
Nucleic acid encoded runx3 transcription factor
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025036992A1
(en)
|
2023-08-16 |
2025-02-20 |
CureVac SE |
Rna conjugates
|
|
CN117362360A
(zh)
*
|
2023-08-21 |
2024-01-09 |
星锐医药(苏州)有限公司 |
一种帽类似物的制备方法
|
|
WO2025054401A2
(en)
*
|
2023-09-06 |
2025-03-13 |
Trilink Biotechnologies, Llc |
Cap analogs and methods of use thereof
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025071359A1
(ko)
|
2023-09-27 |
2025-04-03 |
한미정밀화학 주식회사 |
mRNA 캡 유사체 및 이의 용도
|
|
WO2025088088A1
(en)
|
2023-10-27 |
2025-05-01 |
CureVac SE |
Rna composition for improving cell therapy
|
|
WO2025101994A2
(en)
|
2023-11-10 |
2025-05-15 |
Intellia Therapeutics, Inc. |
Compositions, methods, and systems for genomic editing
|
|
WO2025103803A1
(en)
|
2023-11-13 |
2025-05-22 |
CureVac SE |
Immunotherapy against neuronal and brain tumors
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025147660A2
(en)
|
2024-01-04 |
2025-07-10 |
Trilink Biotechnologies, Llc |
Modified rna for increasing protein expression
|
|
CN117534719B
(zh)
|
2024-01-09 |
2024-05-14 |
北京悦康科创医药科技股份有限公司 |
一种c6'取代锁核酸修饰加帽类似物及其应用
|
|
US20250269059A1
(en)
|
2024-02-27 |
2025-08-28 |
Crispr Therapeutics Ag |
Rt editing compositions and methods
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025201659A1
(en)
|
2024-03-28 |
2025-10-02 |
BioNTech SE |
Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
US12492420B2
(en)
|
2024-03-29 |
2025-12-09 |
New England Biolabs, Inc. |
Compositions, kits, and methods for in vitro transcription
|
|
EP4650358A3
(en)
*
|
2024-04-26 |
2026-01-14 |
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. |
Ribose-modified cap analog and use thereof
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025242815A1
(en)
|
2024-05-23 |
2025-11-27 |
CureVac SE |
Immunotherapy of squamous cell carcinoma
|
|
WO2025264662A1
(en)
|
2024-06-18 |
2025-12-26 |
BioNTech SE |
Compositions and methods for treatment of melanoma
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026010855A1
(en)
|
2024-07-02 |
2026-01-08 |
Trilink Biotechnologies, Llc |
Modified rna for increasing protein expression
|
|
WO2026033380A1
(en)
|
2024-08-05 |
2026-02-12 |
BioNTech SE |
Process for preparing oligosaccharide complexes
|
|
WO2026078020A2
(en)
|
2024-10-07 |
2026-04-16 |
Explorna Therapeutics Sp. Z O. O. |
Efficient in vitro transcription of artificial mrna with highly modified 5' ends
|
|
EP4722375A1
(en)
|
2024-10-07 |
2026-04-08 |
ExploRNA Therapeutics Sp. z o. o. |
Efficient in vitro transcription of artificial mrna with highly modified 5' ends
|
|
CN120608113B
(zh)
*
|
2024-11-29 |
2026-04-10 |
上海蓝鹊生物医药有限公司 |
一种合成Cap2结构5'-加帽RNA的组合和方法
|
|
CN119306779A
(zh)
*
|
2024-12-13 |
2025-01-14 |
上海科泽永欣生物科技有限公司 |
一种含r构型的起始加帽寡核苷酸引物及其合成方法
|